Market News & Trends
UM171 Cell Therapy Demonstrates Improved Outcomes Compared to Cord & Matched Unrelated Donor Peripheral Blood Transplants in Real-World Setting
ExCellThera Inc. recently announced findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with….
FDA Accepts Biogen Biologics License Application for Biosimilar Candidate Referencing ACTEMRA (tocilizumab)
Biogen Inc. recently announced the US FDA has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA (tocilizumab),…
Quotient Sciences Celebrates Grand Opening of New Drug Substance Facility with Official Ribbon Cutting
Quotient Sciences, the drug development and manufacturing accelerator, will hold an official ribbon cutting event in celebration of the grand opening of their new drug…
Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Belgium
Catalent recently announced the completion and opening of a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in….
Metrion Biosciences & The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder
Metrion Biosciences Limited and The KCNC1 Foundation recently announced a collaboration to progress a hit identification research project for small molecule modulators of the….
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
VYNE Therapeutics Inc. recently announced GB Patent No. 2597228, titled Compounds Comprising N-Methyl-2-Pyridone, And Pharmaceutically Acceptable Salts, has been granted by the United Kingdom’s Intellectual Property…
Esperion Announces CLEAR Cardiovascular Outcomes Trial Meets Primary Endpoint
Esperion recently announced the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction…
Gerresheimer to Expand Significantly in High Value Solutions & Further Accelerates its Sustainable Profitable Growth
Gerresheimer AG recently reaffirmed its growth agenda and increased its revenue and adjusted EBITDA guidance. The company continues to execute consistently its formula g strategy…
Summit Therapeutics Partners With Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
Summit Therapeutics Inc. recently announced a definitive agreement of its partnership with Akeso Inc. to in-license its breakthrough bispecific antibody, ivonescimab…..
Evonik Launches Plant-Based Squalene to Boost Vaccine Efficacy
Evonik has recently launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene on the market…
Incannex Expands Intellectual Property Position Over IHL-42X
Incannex Healthcare Limited recently announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of Obstructive Sleep Apnoea….
Enzyvant Announces Merger With Altavant
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology….
Ocuphire Pharma Announces Submission of NDA for Eye Drops for Reversal of Mydriasis
Ocuphire Pharma, Inc. recently announced the submission of a New Drug Application (NDA) to the US FDA for Phentolamine Ophthalmic Solution 0.75% (Nyxol) for the…
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS
ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS….
RespireRx Enters Collaboration With National Institute for Neurological Disorders & Stroke to Advance its Lead GABAkine Toward Clinical Development
RespireRx Pharmaceuticals Inc. recently announced it has been accepted into the NIH HEAL Initiative NINDS Preclinical Screening Platform for Pain (PSPP) program. The company’s lead…
Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase Technology in Support of its Disruptive CDMO Service Offering
Wheeler Bio, Inc. recently announced it has been granted a license to ATUM’s proprietary Leap-In Transposase and miCHO cell line development technology…..
Ventyx Biosciences Announces Dosing of the First Patient in Phase 2 SERENITY Trial for the Treatment of Moderate-to-Severe Plaque Psoriasis
Ventyx Biosciences, Inc. recently announced the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for the…
Catalent Completes Expansion of Clinical Supply Facility in Shanghai, China
Catalent recently announced it has completed the expansion of its clinical supply facility in the Waigaoqiao Free Trade Zone (FTZ) in Shanghai, China. The project…
Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B & Chronic Hepatitis D
Bluejay Therapeutics recently announced it received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to…
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria & Provides Business Update
Synlogic, Inc. recently announced SYNB1353 has achieved proof of mechanism and positive results in a Phase 1 study in healthy volunteers treated with multiple ascending…
